Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | GL-ONC1 |
Synonyms | |
Therapy Description |
Olvimulogene nanivacirepvec (GL-ONC1) is a genetically engineered light-emitting oncolytic vaccinia virus, which results in viral infection within the cells, thereby possibly inducing cell death and interruption of the cell cycle (PMID: 28679776, PMID: 31567308). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
GL-ONC1 | GLV-1h68|Olvimulogene nanivacirepvec|Olvi-Vec | Olvimulogene nanivacirepvec (GL-ONC1) is a genetically engineered light-emitting oncolytic vaccinia virus, which results in viral infection within the cells, thereby possibly inducing cell death and interruption of the cell cycle (PMID: 28679776, PMID: 31567308). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02759588 | Phase Ib/II | GL-ONC1 | GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent Ovarian Cancer | Completed | USA | 0 |
NCT03420430 | Expanded access | GL-ONC1 | Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care | No longer available | USA | 0 |